铁羧葡胺增强MR静脉成像用于糖尿病患者下肢静脉网成像及静脉曲张评估
本研究为铁羧葡胺仿制药II期临床试验的一部分,纳入11例糖尿病患者,在3T MRI上行铁羧葡胺增强MR静脉成像(FE-MRV),评估图像质量、信号强度比、穿通支直径及深-浅静脉网管腔信号均匀性,并检测下肢静脉曲张。结果显示FE-MRV安全、可重复性好,能显示深浅静脉曲张,为术前评估提供「一站式」成像策略。
要点
- FE-MRV可快速全面显示糖尿病患者下肢静脉网及腹盆腔静脉。
- 两位观察者图像质量评分一致性强(κ=0.90),信号强度比ICC为0.72。
- 膝下段异质性指数显著高于膝上段(p=0.039)。
核心结论
- FE-MRV安全且稳健地完成全下肢静脉网成像,可检测并术前评估糖尿病患者浅表和深部静脉曲张。
研究设计与样本
- 铁羧葡胺仿制药II期临床试验的一部分,纳入有记录的糖尿病患者11例,在3T MRI系统上行FE-MRV,两位观察者评估275个静脉段。
关键影像表现/征象
- 两位观察者评估275个静脉段的平均图像质量评分为3.4±0.6。
- 深静脉与隐静脉网管腔信号均匀性分别为0.13±0.05与0.08±0.03。
- 膝下段异质性指数显著高于膝上段(p=0.039)。
- 浅表静脉曲张见于64%(7/11)患者的55%(12/22)患肢。
- 小腿肌内静脉曲张见于9例患者的64%(14/22)患肢。
诊断标准与关键数值
- 图像质量两位观察者强一致(κ=0.90)。
- 信号强度比测量观察者间一致性ICC为0.72。
- 穿通支直径测量观察者间一致性ICC为0.64。
临床应用与阅片要点
- FE-MRV可用于糖尿病患者下肢静脉网的全面显示及浅表与深部静脉曲张的检测和术前评估。
- 原文指出该技术可在严重外周动脉疾病发生前检测出糖尿病患者的浅表和深部静脉曲张。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Comprehensive evaluation of lower-extremity varicose veins (VVs) in patients with diabetes is crucial for treatment strategizing. The study aims to assess the feasibility of using ferumoxytol-enhanced MR venography (FE-MRV) for lower-extremity venous mapping and the detection of VVs in patients with diabetes.
MATERIALS AND METHODS: As part of a phase II clinical trial of a generic brand of ferumoxytol, documented patients with diabetes were enrolled and underwent FE-MRV on a 3-Τ MRI system. Two observers assessed FE-MRV images for image quality, signal intensity ratio (SIR), perforator (PV) diameter, and luminal signal uniformity in deep-to-superficial venous networks with the assessment of intra- and inter-rater reliability. FE-MRV was used to detect lower-extremity VVs.
RESULTS: Eleven patients underwent FE-MRV without adverse events. The average image quality, as scored by the two observers who assessed 275 venous segments, was 3.4 ± 0.6. Two observers strongly agreed on image quality (κ = 0.90) and SIR measurements (interclass correlation coefficient [ICC]: 0.72) and had good agreement on PV diameter (ICC: 0.64). FE-MRV revealed uniform luminal signals in deep and saphenous venous networks (0.13 ± 0.05 vs 0.08 ± 0.03). Below-knee segments exhibited a significantly higher heterogeneity index than above-knee (p = 0.039) segments. Superficial VVs were observed in 55% (12/22) of legs in 64% (7/11) of patients. Calf muscle VVs were present in 64% (14/22) of legs in 9 patients.
CONCLUSION: FE-MRV safely and robustly mapped entire lower-extremity venous networks, enabling the detection and pre-treatment evaluation of both superficial, and deep VVs in patients with diabetes.
CLINICAL RELEVANCE STATEMENT: Ferumoxytol-enhanced magnetic resonance venography offers a "one-stop" imaging strategy for the detection and pre-operative evaluation of both superficial and deep VVs in diabetic patients.
KEY POINTS: Diabetic patients with VVs are at a higher risk of ulcer-related complications. FE-MRV allowed rapid and comprehensive visualization of the lower-limb venous networks and abdominopelvic veins in diabetic patients. This technique allowed for the detection of superficial and deep VVs in diabetic patients before the development of severe peripheral artery disease.
引用
- Liu Y, Cao B, Wang X, et al. Ferumoxytol-enhanced MR venography for mapping lower-extremity venous networks and evaluating varicose veins in patients with diabetes. Eur Radiol. 2024. PMID: 38713277. doi:10.1007/s00330-024-10772-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。